Did You Know...
...that one person who claimed to be the inventor of the television is Russian emigre Vladimir Zworykin? In 1929 David Sarnoff, founder of RCA, asked Zworykin what it would take to develop TV for commercial use. He said: a year and a half and $100,000. In reality, it took 20 years and $50 million! Before his death in 1982 at the age of 92, Zworykin said of his invention: "The technique is wonderful. It is beyond my expectations. But the programs! I would never let my children even come close to this thing."
PatentStorm News
Make the Most of PatentStorm
See this month's Top Inventors and Most Cited Patents.
Stay on top of the latest patents by subscribing to an RSS feed.
Got questions? Ask a Patent Expert!
Registered users: Manage your profile, comments and alerts.
US Patent 7094410 - DNA vaccine against proliferating endothelial cells and methods of use thereof
US Patent Issued on August 22, 2006
Estimated Patent Expiration Date:
March 2, 2022Estimated Expiration Date is calculated based on simple USPTO term provisions. It does not account for terminal disclaimers, term adjustments, failure to pay maintenance fees, or other factors which might affect the term of a patent.
Estimated Patent Expiration Date:
March 2, 2022Estimated Expiration Date is calculated based on simple USPTO term provisions. It does not account for terminal disclaimers, term adjustments, failure to pay maintenance fees, or other factors which might affect the term of a patent.AbstractA DNA vaccine effective for inhibiting endothelial cell proliferation comprises a DNA construct operably encoding a vascular endothelial growth factor (VEGF) receptor protein. This invention provides DNA vaccines that encode VEGF receptor-2 (KDR, SEQ ID NO: 2), VEGF receptor-1 (Flt-1, (SEQ ID NO: 4), or Flk-1 (the murine homolog of KDR, SEQ ID NO: 6), DNA sequences SEQ ID NOS: 1, 3, and 5 respectively, as well as methods of using such a DNA vaccine to inhibit vascular endothelial cell proliferation in the tumor micro-environment. Anti-angiogenesis and subsequent decrease in tumor growth and dissemination is achieved.Other References
| InventorsApplicationNo. 10090183 filed on 03/02/2002US Classes:424/200.1, Recombinant or stably-transformed bacterium encoding one or more heterologous proteins or fragments thereof424/185.1, Amino acid sequence disclosed in whole or in part; or conjugate, complex, or fusion protein or fusion polypeptide including the same424/93.1, WHOLE LIVE MICRO-ORGANISM, CELL, OR VIRUS CONTAINING424/93.2, Genetically modified micro-organism, cell, or virus (e.g., transformed, fused, hybrid, etc.)424/93.4, Bacteria or actinomycetales435/252.3Transformants (e.g., recombinant DNA or vector or foreign or exogenous gene containing, fused bacteria, etc.)Field of Search424/93.2, Genetically modified micro-organism, cell, or virus (e.g., transformed, fused, hybrid, etc.)514/44, Polynucleotide (e.g., RNA, DNA, etc.)435/252.3Transformants (e.g., recombinant DNA or vector or foreign or exogenous gene containing, fused bacteria, etc.)ExaminersPrimary: Priebe, Scott D.Assistant: Burkhart, Michael Attorney, Agent or FirmUS Patent References5851999, FLK-1 is a receptor for vascular endothelial growth factorIssued on: 12/22/1998 Inventor: Ullrich, et al.5939400, DNA vaccination for induction of suppressive T cell response Issued on: 08/17/1999 Inventor: Steinman, et al.6086891Bi-functional plasmid that can act as both a DNA vaccine and a recombinant virus vector Issued on: 07/11/2000 Inventor: Hurwitz, et al. Foreign Patent References
International ClassesA61K 39/00A61K 48/00 C12N 1/21 A01N 63/00 |
